PedAM
Pediatric Disease Annotations & Medicines
| Disease | psoriatic arthritis |
| Phenotype | C0003864|inflammatory arthritis |
| Sentences | 3 |
| PubMedID- 25438647 | Background: the data in the literature concerning the frequency of remission of inflammatory arthritis in patients with psoriatic arthritis (psa) are limited and conflicting. |
| PubMedID- 20231209 | Risk factors for axial inflammatory arthritis in patients with psoriatic arthritis. |
| PubMedID- 22915624 | Mri assessment of abatacept-treated patients has previously been reported in the adjust trial in mtx-naive patients with very early or undifferentiated inflammatory arthritis, and in patients with psoriatic arthritis.2324 the improvements in mri synovitis, osteitis and erosion progression seen here with abatacept plus mtx over 12 months are consistent with findings from those trials, and with pharmacodynamic data that suggest abatacept may have a positive effect on bone metabolism through its regulatory effect on osteoclast differentiation and bone resorption.20 the degree of local baseline inflammation, both synovitis and osteitis, predicts erosion progression during early disease.25–27 consequently, improving osteitis scores may favourably impact the long-term prognosis of erosion progression. |
Page: 1